The repository will provide phenotypic, proteomic, metabolomic, genomic datasets, treatment protocols, and more from, potentially, 10,000 autism patients and families.
The study will enroll 1,500 subjects, including autistic and typically developing children, to discover and validate biomarkers that may enable earlier diagnosis and better treatment of ASD.
The public-private consortium aims to develop and disseminate stem cell-based technologies and assays to study autism spectrum disorder and other mental health diseases.
In PNAS this week: regenerative flatworm genome, transmission patterns of autism-linked de novo mutations, and more.
Researchers found that array-based testing and exome sequencing contributed uniquely to ASD diagnosis, and that the diagnostic yield of testing was higher in complex autism cases.
BioTeam has developed a web portal for the MSSNG repository that offers easy access to genomic, phenotype, and clinical data collected through the project.
The study is part of the Biomarkers Consortium, and will include the collection of DNA samples for future genomics research into ASD.
Advances in genetic technologies are paving the way to elucidate the pathophysiology of autism, according to an article in Lancet Neurology.
A $4.6 million Simons Foundation grant will fund enrollment and initial data collection, but additional resources are necessary for genetic analysis and hypothesis generation.
Harvard Medical School's Kaitlin Samocha is studying de novo mutations linked to complex diseases like autism and schizophrenia.
A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.
The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.
Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.
In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.